New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 6, 2014
08:06 EDTSTEMStemCells CEO says difficult to understand stock performance last year
StemCells posted a letter to shareholders from its President and CEO Martin McGlynn, stating in part: "As CEO, one of my easiest and most gratifying jobs is to report our persistent progress to you real evidence that StemCells, Inc. continues to be a clear frontrunner. What is more difficult is trying to understand our Company's stock performance for the year just ended. We have reached out to usually well-informed third parties in the analyst and investor communities to help us understand this dynamic, but have been unable to identify anything unusual or particularly enlightening...StemCells, Inc. is in the unique position of concurrently developing novel product candidates for major medical conditions that have thus far defied traditional treatments, in all three components of the CNS: the spinal cord...the eye...and the brain...If we succeed in bringing our HuCNS-SC cells to market for even one of these indications, we believe it will be very meaningful to patients, shareholders and society at large...In 2013, we closed on approximately $54.6M in fresh capital, $29.3M of which is debt, including the committed forgivable loan from the CIRM of up to $19.3M. We start 2014 with a little over $30M in the bank, and we expect to receive the second tranche of non-dilutive funding from the CIRM, again $3.8M, later this month."
News For STEM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 16, 2015
08:13 EDTSTEMStemCells completes enrollment in first cohort of Phase II Pathway Study
StemCells announced that it has completed transplanting the six patients comprising the first cohort of its Phase II Pathway Study. The first cohort is an open-label dose escalation arm to determine the cell dose to be used for the second cohort of the study. The second cohort of the study is a single-blind arm in 40 patients that will assess efficacy of the company's proprietary HuCNS-SC platform technology for the treatment of cervical spinal cord injury.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use